StreetInsider.com News Articles

Form 8-K WEST PHARMACEUTICAL SERV For: Jul 14

Tue, 14 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260714/26768575.html

Form 8-K WEST PHARMACEUTICAL SERV For: Jul 14

Tue, 14 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260714/26768575.html

BNP Paribas Exane Starts West Pharmaceutical (WST) at Outperform

Mon, 13 Jul 2026 07:21:54 -0400

BNP Paribas Exane initiates coverage on West Pharmaceutical (NYSE: WST) with a Outperform rating and a price target of $447.00.

For an analyst ratings summary and ratings history on West Pharmaceutical click here. For more ratings news on West Pharmaceutical click here.

Shares of West Pharmaceutical closed at $353.71 yesterday.

West Pharmaceutical (WST) PT Raised to $365 at Morgan Stanley

Thu, 09 Jul 2026 08:16:42 -0400

Morgan Stanley analyst Kallum Titchmarsh raised the price target on West Pharmaceutical (NYSE: WST) to $365.00 (from $325.00) while maintaining a Equalweight rating.

West to Host Second-Quarter 2026 Conference Call

Tue, 07 Jul 2026 06:00:00 -0400

EXTON, Pa., July 7, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2026 financial results before the market opens on Thursday, July 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.

West to Host Second-Quarter 2026 Conference Call

Tue, 07 Jul 2026 06:00:00 -0400

West to Host Second-Quarter 2026 Conference Call

Tue, 07 Jul 2026 06:00:00 -0400

West to Host Second-Quarter 2026 Conference Call

Tue, 07 Jul 2026 06:00:00 -0400

West Pharmaceutical (WST) PT Raised to $390 at KeyBanc

Thu, 02 Jul 2026 06:51:05 -0400

KeyBanc analyst Paul Knight raised the price target on West Pharmaceutical (NYSE: WST) to $390.00 (from $350.00) while maintaining a Overweight rating.

Form 4 WEST PHARMACEUTICAL SERV For: Jun 30 Filed by: HAUGEN JANET BRUTSCHEA

Wed, 01 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26722522.html

Form 4 WEST PHARMACEUTICAL SERV For: Jun 30 Filed by: HAUGEN JANET BRUTSCHEA

Wed, 01 Jul 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260701/26722522.html

West Pharmaceutical sells SmartDose 3.5mL on-body delivery system rights

Wed, 01 Jul 2026 16:30:11 -0400

West Pharmaceutical Services, Inc. (NYSE: WST) announced it completed the sale and transfer of manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System, along with associated facilities, on July 1, 2026.

The Exton, Pennsylvania-based company stated it will continue to develop and manufacture other versions of the SmartDose platform, including the SmartDose® 10mL On-Body Delivery System.

No financial terms of the transaction were disclosed in the company's statement.

West Pharmaceutical sells SmartDose 3.5mL on-body delivery system rights

Wed, 01 Jul 2026 16:30:11 -0400

The Exton, Pennsylvania-based company stated it will continue to develop and manufacture other versions of the SmartDose platform, including the SmartDose® 10mL On-Body Delivery System.

No financial terms of the transaction were disclosed in the company's statement.

West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System

Wed, 01 Jul 2026 16:30:00 -0400

EXTON, Pa., July 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the company completed the sale and transfer of the manufacturing and supply rights for SmartDose® 3.5mL On-Body Delivery System and associated facilities. The transaction closed as planned on July 1, 2026.

West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System

Wed, 01 Jul 2026 16:30:00 -0400

West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System

Wed, 01 Jul 2026 16:30:00 -0400

West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System

Wed, 01 Jul 2026 16:30:00 -0400

West Pharma (WST) June calls active

Wed, 10 Jun 2026 05:37:49 -0400

West Pharma (NYSE: WST) 30-day option implied volatility is at 34; compared to its 52-week range of 24 to 64 with a focus on June calls.

Barclays Upgrades West Pharmaceutical (WST) to Overweight

Tue, 09 Jun 2026 06:26:27 -0400

(Updated - June 9, 2026 6:26 AM EDT)

Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).

The analyst comments "We upgrade WST to Overweight and increase our price target to $400. When we initiated on the stock at Equal Weight last year, our key reason for staying on the sidelines was mainly around the risk from multi-dose vials to the business, plus the implications of oral GLP-1s coming to market. We admittedly overestimated these potential headwinds and have now done some work that suggests it should not be as

Barclays Upgrades West Pharmaceutical (WST) to Overweight

Tue, 09 Jun 2026 06:26:27 -0400

(Updated - June 9, 2026 6:26 AM EDT)

Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).

Barclays Upgrades West Pharmaceutical (WST) to Overweight

Tue, 09 Jun 2026 06:26:27 -0400

(Updated - June 9, 2026 6:26 AM EDT)

Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).

Barclays Upgrades West Pharmaceutical (WST) to Overweight

Tue, 09 Jun 2026 06:26:27 -0400

(Updated - June 9, 2026 6:26 AM EDT)

Barclays analyst Luke Sergott upgraded West Pharmaceutical (NYSE: WST) from Equalweight to Overweight with a price target of $400.00 (from $310.00).

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Investing.com -- Jefferies released a research report Tuesday examining artificial intelligence adoption across pharmaceutical services companies, based on analysis of 42 expert call transcripts from the past 90 days.

The firm used AI tools to review commentary on AI implementation across contract research organizations and drug development processes. Expert identities were kept anonymous with only credentials provided.

The analysis found AI produces efficiency gains that vary by development stage. Early discovery and regulatory writing showed cost savings of approximately 40% to 50%, while preclinical workflows at CROs and contract development and manufacturing organizations saw time reductions of about 40% to 50%. Later-stage

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400

Jefferies finds AI drives up to 50% cost cuts in drug development

Tue, 02 Jun 2026 12:32:48 -0400